Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10064916 | 0.82 | ALDH1A1 (0.39) | SMN1; SMN2L3MBTL1ALDH1A1TDP1POLB | |
| SCHEMBL954785 | 0.81 | MEN1 (0.43) | SMN1; SMN2L3MBTL1ALDH1A1TDP1POLB | |
| SCHEMBL957932 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2L3MBTL1ALDH1A1HPGD | |
| SCHEMBL5907732 | 0.78 | ALDH1A1 (0.39) | SMN1; SMN2L3MBTL1ALDH1A1TDP1POLB | |
| SCHEMBL1641183 | 0.77 | CFTR (0.40) | SMN1; SMN2L3MBTL1ALDH1A1HPGD | |
| SCHEMBL954180 | 0.74 | ALDH1A1 (0.36) | L3MBTL1ALDH1A1TDP1POLB | |
| SCHEMBL27804806 | 0.73 | S1PR2 (0.35) | ALDH1A1TDP1HPGD | |
| SCHEMBL17032805 | 0.72 | ALDH1A1 (0.46) | SMN1; SMN2L3MBTL1ALDH1A1TDP1POLB | |
| SCHEMBL1959772 | 0.70 | GRM5 (0.43) | SMN1; SMN2L3MBTL1ALDH1A1POLBHPGD | |
| SCHEMBL1960610 | 0.70 | SMN1; SMN2 (0.35) | SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8617723-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| US-20110012100-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110012100-A1 | METAL COMPLEXES | AP1M1, AP3M1, SOD1 | SMN1; SMN2 3529/4885L3MBTL1 3656/4885ALDH1A1 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.